• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
CONCLUSION: In tofacitinib-treated patients with PsA/PsO, increased ASCVD risk and baseline MetS were associated with higher IRs for MACE and malignancies. Our results support assessing CV risk in patients with PsA/PsO and suggest enhanced cancer monitoring in those with increased ASCVD risk.REGISTRATION CLINICALTRIALSGOV: NCT01877668/NCT01882439/NCT01976364/NCT00678210/NCT01710046/NCT01241591/NCT01186744/NCT01276639/NCT01309737/NCT01163253.PLAIN LANGUAGE SUMMARY: People who have psoriatic arthritis or psoriasis may have more heart-related problems and cancer if they have a higher risk of cardiovascular disease: A study in...
Source: Adv Data - February 13, 2023 Category: Epidemiology Authors: Lars E Kristensen Bruce Strober Denis Poddubnyy Ying-Ying Leung Hyejin Jo Kenneth Kwok Ivana Vranic Dona L Fleishaker Lara Fallon Arne Yndestad Dafna D Gladman Source Type: research

Increasing Upstream Chromatin Long –Range Interactions May Favor Induction of Circular RNAs in LysoPC-Activated Human Aortic Endothelial Cells
We examined the sponging potential of all significantly changed circRNAs using the CircInteractome database (Montefiori et al., 2018), recording two miRNAs with four or more predicted binding sites in a single circRNA transcript, a threshold above which meaningful sponging activity is likely to occur Memczak et al. (2013). Another four significantly changed circRNAs are experimentally shown to sponge miRNAs (Dudekula et al., 2016; Chen et al., 2017; Yan et al., 2017; Wang et al., 2018), for six total circRNAs with miRNA sponging activity including miR125, miR143, miR1272, miR153, miR515-5p, and miR196a-5p (Table 4). In Fig...
Source: Frontiers in Physiology - April 17, 2019 Category: Physiology Source Type: research

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial
ConclusionsTildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis.
Source: British Journal of Dermatology - October 15, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Clinical Trials Source Type: research

Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial.
CONCLUSIONS: Tildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731 This article is protected by copyright. All rights reserved. PMID: 26042589 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - June 3, 2015 Category: Dermatology Authors: Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R Tags: Br J Dermatol Source Type: research

Tildrakizumab (MK‐3222), an Anti‐ IL‐23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo‐ Controlled Trial
ConclusionsTildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 1, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Original Article Source Type: research